Novartis | NVS - Cash And Equivalent


Novartis reported $6.88B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bausch Health Companies USD 1.83B 526M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Canopy Growth CAD 364.68M 6.64M Mar/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Drreddys Laboratories INR 15.37B 3.29B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
J&J USD 20.42B 1.27B Jun/2026
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 7.62B 739M Jun/2026
Novartis USD 6.88B 2.68B Mar/2026
Pacira USD 205.88M 61.57M Jun/2026
Perrigo USD 357.2M 174.4M Mar/2026
Pfizer USD 976M 727M Jun/2026
Phibro Animal Health USD 54.93M 557K Mar/2026
Prestige Brands USD 89.13M 25.26M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Sanofi EUR 5.54B 2.11B Mar/2026
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026
Zoetis USD 1.94B 369M Mar/2026